Daniel T. Kajunski

Offerings for Public Companies

• Represented Vertex Pharmaceuticals (Nasdaq: VRTX) in over $2.0 billion in equity and debt offerings since 2006
• Represented ImmunoGen (Nasdaq: IMGN) in approximately $350 million in equity offerings since 2008
• Represented Amedica (Nasdaq: AMDA) in its IPO
• Represented the underwriters in the IPO of Calithera Biosciences (Nasdaq: CALA)
• Represented the underwriters in the IPO of American Depositary Shares of GW Pharmaceuticals (Nasdaq: GWPH) and two additional follow-on offerings

Venture Capital & Strategic Financings

• Represented a public technology company in the semiconductor and life sciences industry (Nasdaq) in multiple strategic investments
• Represented a public medical device company (NYSE) in multiple strategic investments
• Represented Clarus Ventures in its investments in Ophthotech (Nasdaq: OPHT), VBI Vaccines (Nasdaq: VBIV), TyRx Pharma, and Link Medicine
• Represented a public biotechnology company (Nasdaq) in its strategic equity investment in a private biotechnology company
• Represented Style Me Pretty in its strategic investment from AOL (NYSE: AOL)
• Represented Synchroneuron in multiple equity financings
• Represented TransMolecular in multiple equity and debt financings
• Represented Ion Torrent Systems in multiple equity financings
• Represented I-Pulse in multiple equity financings
• Represented TransForm Pharmaceuticals in multiple equity financings
• Represented Hemera Biosciences in its Series A financing

Mergers & Acquisitions

• Represented Brooks Automation (Nasdaq: BRKS) in its purchase of BioStorage Technologies
• Represented a public biotechnology company (Nasdaq) in its entering into a merger option to acquire a private biotechnology company
• Represented Clarus Ventures in the reverse merger of VBI Vaccines (Nasdaq: VBIV) with Paulson Capital
• Represented Orchid BioSciences (Nasdaq: ORCH) in its sale to Laboratory Corporation of America (NYSE: LH)
• Represented QIAGEN (Nasdaq: QGEN) in its purchase of SA Biosciences
• Represented TransMolecular in its sale to Morphotek (a subsidiary of Eisai Co. (Tokyo Stock Exchange))
• Represented Auspice in its sale to the ARRIS Group (Nasdaq: ARRS)
• Represented EPIX Pharmaceuticals (Nasdaq: EPIX) in its merger with Predix Pharmaceuticals
• Represented TransForm Pharmaceuticals in its sale to Johnson & Johnson (NYSE: JNJ)
• Represented FastClick (Nasdaq: FSTC) in its sale to ValueClick (Nasdaq: VCLK)